



## *cIAP1* inhibitor of apoptosis is a tumor suppressor in Ewing sarcoma

Florencia Cidre-Aranaz<sup>a,b,c,\*</sup>, Florian H. Geyer<sup>a,b,c,d</sup>, Tilman L.B. Hölting<sup>a,b,c</sup>,  
 Kimberley M. Hanssen<sup>a,b,c</sup>, Tobias Faehling<sup>a,b,c,d</sup>, Alina Ritter<sup>a,b,c,d</sup>,  
 Malenka Zimmermann<sup>a,b,c,d</sup>, Lianghao Mao<sup>e</sup>, Javier Alonso<sup>f,g</sup>, Ana Sastre<sup>h</sup>,  
 Ashok Kumar Jayavelu<sup>e</sup>, Maximilian M.L. Knott<sup>a,b,c</sup>, Julian Musa<sup>a,b,c,i</sup>,  
 Thomas G.P. Grünwald<sup>a,b,c,j,\*\*</sup>

<sup>a</sup> Hopp Children's Cancer Center Heidelberg (KiTZ), Heidelberg, Germany

<sup>b</sup> National Center for Tumor Diseases (NCT), NCT Heidelberg, a Partnership Between DKFZ and Heidelberg University Hospital, Heidelberg, Germany

<sup>c</sup> Division of Translational Pediatric Sarcoma Research, German Cancer Research Center (DKFZ), German Cancer Consortium (DKTK), Heidelberg, Germany

<sup>d</sup> Faculty of Medicine, Heidelberg University, Heidelberg, Germany

<sup>e</sup> Proteomics and Cancer Cell Signaling Group, German Cancer Research Center (DKFZ), Heidelberg, Germany

<sup>f</sup> Unidad de Tumores Sólidos Infantiles, Instituto de Investigación de Enfermedades Raras, Instituto de Salud Carlos III, Madrid, Spain

<sup>g</sup> Centro de Investigación Biomédica en Red de Enfermedades Raras, Instituto de Salud Carlos III (CB06/07/1009, CIBERER-ISCIH), Spain

<sup>h</sup> Unidad por Servicio de Hemato-Oncología Pediátrica, Hospital Infantil Universitario La Paz, Madrid, Spain

<sup>i</sup> Department of General, Visceral, Thoracic, and Transplant Surgery, University Hospital of Giessen and Marburg, Giessen, Germany

<sup>j</sup> Institute of Pathology, Heidelberg University Hospital, Heidelberg, Germany

### ARTICLE INFO

#### Keywords:

Ewing sarcoma  
*cIAP1*  
*BIRC2*  
 Pediatric sarcoma  
 Apoptosis

### ABSTRACT

Ewing sarcoma (EwS) is a highly aggressive pediatric malignancy driven by *EWSR1::ETS* fusion oncoproteins –primarily *EWSR1::FLI1*– which deregulate genes essential for differentiation, proliferation, and cell survival. To uncover key downstream targets of this fusion involved in cell differentiation, we combined transcriptomic profiling of EwS cell lines following *EWSR1::ETS* inhibition with gene ontology analysis, a clinically annotated gene expression dataset derived from EwS patient material and network analyses. This integrative approach identified inhibitor of apoptosis protein 1 (*cIAP1*, alias *BIRC2*) as an *EWSR1::FLI1*-suppressed gene. Despite its known oncogenic role in many cancers, *cIAP1* showed minimal expression in EwS. Using inducible *cIAP1* re-expression models in EwS cells, we demonstrated that *cIAP1* re-expression suppresses proliferation, clonogenic growth, and 3D spheroid formation *in vitro*. Transcriptomic and proteomic analyses revealed that low *cIAP1* expression enhances proliferation-related gene signatures, which are inhibited upon *cIAP1* re-expression. *In vivo* xenograft models revealed that *cIAP1* re-expression significantly reduces tumor growth, mitotic activity, and Ki-67 positivity, while increasing tumor necrosis and apoptosis. These findings highlight an unexpected tumor-suppressive role for *cIAP1* in fusion-driven EwS, contrasting with its pro-survival function in other cancers. Collectively, our results identify *cIAP1* as a prognostically relevant, *EWSR1::FLI1*-regulated hub whose re-expression disrupts tumor progression, offering a potential therapeutic strategy to restore tumor-suppressive pathways in EwS.

### 1. Main text

Ewing sarcoma (EwS) is an aggressive pediatric cancer with dismal overall survival rates for patients with relapsed or metastatic disease

(<30% overall survival rates) [1]. It is mainly characterized by a single genetic alteration: a chromosomal translocation fusing a member of the FET (*FUS*, *EWSR1*, *TAF15*) family of genes with an ETS transcription factor (mainly *FLI1* or *ERG*). The encoded FET::ETS fusion proteins (in

\* Corresponding author. Division of Translational Pediatric Sarcoma Research, German Cancer Research Center (DKFZ) & Hopp Children's Cancer Center (KiTZ), Im Neuenheimer Feld 280, 69210, Heidelberg, Germany.

\*\* Corresponding author. Division of Translational Pediatric Sarcoma Research German Cancer Research Center (DKFZ) & Hopp-Children's Cancer Center (KiTZ), Im Neuenheimer Feld 280, 69210, Heidelberg, Germany.

E-mail addresses: [florencia.cidrearanaz@dkfz.de](mailto:florencia.cidrearanaz@dkfz.de) (F. Cidre-Aranaz), [t.gruenewald@kitz-heidelberg.de](mailto:t.gruenewald@kitz-heidelberg.de) (T.G.P. Grünwald).

<https://doi.org/10.1016/j.canlet.2026.218389>

Received 17 October 2025; Received in revised form 19 February 2026; Accepted 27 February 2026

Available online 2 March 2026

0304-3835/© 2026 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC license (<http://creativecommons.org/licenses/by-nc/4.0/>).

~85% of cases *EWSR1::FLI1* and in ~10% *EWSR1::ERG* act as aberrant transcription factors that deregulate a plethora of genes involved in inhibition of cell differentiation, cell-cycle regulation, cell migration and proliferation among others [1].

To identify key *EWSR1::ETS* target genes we devised a systems biology approach where we first analyzed transcriptome profiles of eight EwS cell lines with or without shRNA-mediated knockdown (KD) of *EWSR1::ETS* (KD <30% of baseline expression at mRNA and protein levels, as previously assessed [2]) for 96 h according to the workflow depicted in Fig. 1a. This analysis yielded a list of 1,318 differentially expressed genes (DEGs) being up- or downregulated ( $|\log_2 \text{FC}| \geq 0.75$ ) after KD of *EWSR1::FLI1* across all cell lines. These DEGs were filtered for genes annotated with the gene ontology (GO) term 'Regulation of Cell Differentiation' using PantherDB, which was significantly enriched among the *EWSR1::ETS* regulated DEGs ( $P = 8.77 \times 10^{-10}$ , false-discovery rate (FDR) =  $1.05 \times 10^{-7}$ ). Using the obtained 167 DEGs (Supplementary Table 1), we carried out a network analysis using *Cytoscape* and the *GeneMania* plugin highlighting pathway, physical, and genetic interactions [3] (Fig. 1b). To identify key hubs within this network with potential clinical relevance, we further considered those genes whose expression significantly correlated with overall survival in a cohort of 196 EwS patients with matched gene expression and clinical data ( $P < 0.01$ ). This analysis resulted in 26 network hubs (Supplementary Table 2), out of which the single hub with the strongest correlation with patient overall survival was cellular inhibitor of apoptosis protein 1 (*cIAP1*; alias baculoviral IAP repeat containing 2, *BIRC2*) (Fig. 1b and c;  $P = 0.0001$ ).

Inhibitor of apoptosis proteins are frequently overexpressed in cancer and contribute to therapeutic resistance [4,5]. To explore the specific expression pattern of *cIAP1* in other cancers compared to EwS, we analyzed 15 cancer entities comprising pediatric tumors and EwS morphological mimics using well-curated microarray data from a prior study of our laboratory [6,7]. Interestingly, EwS ranked as the tumor entity with the lowest *cIAP1* expression in primary tumors (Fig. 1d). To illuminate the underlying cause of this expression pattern, we re-analyzed scRNA-seq data from three EwS patient-derived xenografts (*EWSR1::FLI1* expression) [8], and two primary cultures of mesenchymal stem cells –proposed cells of EwS origin [9]– negative for *EWSR1::FLI1* [8]. A comparative analysis showed a significantly lower *cIAP1* expression in the EwS-derived samples (Fig. 1e), suggesting a potential regulatory mechanism between *EWSR1::FLI1* and *cIAP1*. To explore this possibility, we reanalyzed the *cIAP1* locus in ChIP-seq data [2] derived from the same eight EwS cell lines as in Fig. 1a. Inspection of the *cIAP1* promoter region revealed a specific *EWSR1::FLI1* binding in this region in 7/8 cell lines analyzed (Suppl. Fig. 1a). This peak coincided with a H3K27ac mark that became specifically active upon inhibition of *EWSR1::FLI1* in both A-673 and SK-N-MC cell lines, indicating a potential repressive activity of *EWSR1::FLI1* on *cIAP1* (Suppl. Fig. 1a). Further correlation analyses on a published gene expression dataset comprising 18 EwS cell lines with shRNA-mediated KD of *EWSR1::FLI1/ERG* for 96 h [2] showed that stronger *EWSR1::ETS* KD significantly correlated with higher *cIAP1* expression (Fig. 1f,  $P = 0.0183$ ;  $r = 0.5$ ). Collectively, these data suggested a strong and likely direct repressive regulation of *cIAP1* by *EWSR1::FLI1* and *EWSR1::ERG*.

To better understand the interplay between *cIAP1* and *EWSR1::ETS*, we generated cell line models containing a doxycycline (DOX)-inducible re-expression of *cIAP1* in two EwS cell lines (SK-N-MC and TC-71), which we found previously to display a high genomic and phenotypic stability contributing to reproducibility of experimental results [10]. It should be noted that the induced *cIAP1* re-expression levels in these two cell lines were comparable to the *cIAP1* levels obtained in the eight EwS cell lines upon shRNA-mediated knockdown (KD) of *EWSR1::ETS* (Fig. 1a, Suppl. Fig. 1b). As shown in Fig. 1g, addition of DOX to the culture medium induced a median of 2.7–3.6-fold re-expression of *cIAP1*

at the mRNA level, while no changes in *cIAP1* expression were observed in control cell lines (Suppl. Fig. 1b). Consistent with the hypothesis that *cIAP1* may be a repressed *EWSR1::ETS* downstream effector, transcriptome profiling of two EwS cell lines after either KD of *EWSR1::FLI1* or re-expression of *cIAP1* showed a highly significant ( $P = 5.15 \times 10^{-75}$  or  $P = 1.4 \times 10^{-84}$ ) overlap of concordant DEGs supporting the idea that *cIAP1* acts as a regulatory downstream hub of the fusion (Fig. 1h).

To further investigate the consequences of *cIAP1* suppression in EwS, and since KD of *EWSR1::ETS* resulted in a significant inhibition of proliferation in EwS cell lines (Suppl. Fig. 1c) that could be at least in part mediated by *cIAP1* re-expression, we performed transcriptome profiling coupled with gene-set enrichment and weighted gene correlation network analysis (WGCNA) of SK-N-MC and TC-71 EwS cells with/without conditional re-expression of *cIAP1*. These analyses demonstrated that low *cIAP1* levels promote the overrepresentation of gene-sets involved in cell proliferation-related signatures (Fig. 1i), which was completely abrogated by *cIAP1* re-expression (Fig. 1i). In agreement with these results, correlation analysis of publicly available proteomic data of four EwS cell lines (including TC-71 and SK-N-MC) showed a striking overrepresentation of proliferation-related signatures being anti-correlated with *cIAP1* expression (Fig. 1j).

Although *cIAP1* overexpression is associated with promoting cancer cell survival and therapy resistance in carcinomas [5,11], its role in fusion-driven sarcomas is less clear. To explore the functional role(s) of *cIAP1* in EwS, we employed our DOX-inducible *cIAP1* re-expression models (SK-N-MC and TC-71). As shown in Fig. 1k, *cIAP1* re-expression significantly reduced ( $P = 0.0022$ ) proliferation in both cell lines (Fig. 1k), which was not observed in empty vector controls (Suppl. Fig. 1e). This reduced proliferative effect was not mediated by an accumulation of cell death (Suppl. Fig. 1f). Moreover, long-term re-expression of *cIAP1* significantly inhibited the capacity for clonogenic growth in two-dimensional (2D) cultures (Fig. 1l, Suppl. Fig. 1g), and anchorage-independent spheroidal growth in 3D (Fig. 1m). Interestingly, when the same two EwS cell lines were engineered to conditionally re-express a *cIAP1* deletion mutant affecting their RING domain ( $\Delta$ RING), which regulates its stability [12], the *cIAP1*-mediated inhibition on EwS clonogenic growth was reverted, suggesting that the RING domain is required to suppress the tumorigenic phenotype of EwS cells (Suppl. Fig. 1h and i).

To investigate whether the strong in vitro anti-tumorigenic role of *cIAP1* could be recapitulated in an *in vivo* setting, TC-71 and SK-N-MC cells with conditional re-expression of *cIAP1* were tested in a pre-clinical xenotransplantation mouse model. For this, each cell line was subcutaneously injected in the right flanks of immunocompromised mice, and once tumors were palpable, DOX (treatment) or sucrose (control) were delivered via the drinking water. As depicted in Fig. 1n, *cIAP1* re-expression (Suppl. Fig. 1j) significantly impaired local tumor growth in both EwS cell lines, which was mirrored by significant decrease in tumor weight (Fig. 1o). Ex vivo immunohistochemical (IHC) evaluation of the tumors showed that *cIAP1* re-expression drastically decreased the mitotic index and Ki-67 immunopositivity (Fig. 1p and q). Strikingly, the xenografts showed a significant difference in tumor necrotic area ( $P = 0.0051$  or  $P = 0.0012$ ) and a tendency to presenting higher apoptotic indices in histological sections (Fig. 1r and s). Similar experiments performed with both cell lines transduced with empty control vectors exhibited no significant differences in these phenotypes upon DOX-treatment as demonstrated previously [13]. These results indicated that *EWSR1::ETS*-mediated downregulation of *cIAP1* promotes clonogenic and anchorage-independent growth as well as tumorigenicity and suppression of cell death of EwS cells.


Collectively, our data show that *cIAP1* is a prognostically-relevant, *EWSR1::ETS*-regulated network hub in EwS, and that its re-expression severely impairs tumor fitness in vitro and *in vivo*.

2. Materials and methods

2.1. Provenience of cell lines and cell culture conditions

Human EwS SK-N-MC (CVCL\_0530) and TC-71 (CVCL\_2213) cell lines were provided by the German Collection of Microorganism and Cell Cultures (DSMZ). HEK293T (CVCL\_0063) were purchased from

American Type Culture Collection (ATCC). All cell lines were cultured in RPMI 1640 medium with stable glutamine (Biochrom, Germany) supplemented with 10% tetracycline-free fetal bovine serum (Sigma-Aldrich, Germany), 100 U/mL penicillin and 100 µg/mL streptomycin (Merck, Germany) at 37 °C with 5% CO<sub>2</sub> in a humidified atmosphere. Cell lines were routinely tested for *Mycoplasma* contamination by nested PCR, and cell line identity was regularly verified by STR-profiling.



(caption on next page)

**Fig. 1.** | Systems biology approach identifies *cIAP1* as a prognostically relevant *EWSR1::FLI1*-regulated key hub displaying antitumorigenic functions in EwS. **a)** Workflow depicting a stepwise systems biology approach to identify DEGs regulated by *EWSR1::FLI1*, involved in regulation of cell differentiation, and associated with overall survival in a cohort of 196 EwS patients. Number of genes represent remaining candidates after each filtering step. **b)** Network of *EWSR1::FLI1*-regulated genes involved in regulation of cell differentiation. Genes are depicted as nodes (circles). Node outline color represent up- (green) or down- (red) regulation by *EWSR1::FLI1*. Node border width represent strength of regulation by *EWSR1::FLI1* (thicker border represents higher the fold-change). Node size represents strength of association with overall survival in a 196 EwS patient cohort. Yellow nodes depict strong and significant association with overall survival ( $P < 0.01$ ). Connecting lines show three types of interconnections between nodes: physical (red), pathway (blue), genetic (green). **c)** Kaplan-Meier survival analysis of 196 primary EwS patients stratified by quintile *cIAP1* expression. Mantel-Haenszel test. DEG: differentially expressed genes; KD: knockdown. **d)** *cIAP1* expression levels of EwS and 14 additional primary pediatric tumors or EwS morphological mimics. Data are represented as bar plots where horizontal bars represent mean and SEM. The number of samples per group ( $n$ ) is given in parentheses. ARMS: alveolar rhabdomyosarcoma; ALL: acute lymphocytic leukemia; PNET: primary neuroectodermal tumors; AML: acute myeloid leukemia. **e)** Analysis of single-cell RNA-Seq data (GSE130025) for *cIAP1* expression comparing EwS patient derived xenografts (PDX) to mesenchymal stem cells (MSC). Rectangles depict *EWSR1::FLI1* expression level (white: low; black: high). Number of analyzed cells is given in parentheses. **f)** *cIAP1* and *EWSR1::ETS* expression in 18 EwS cell lines with conditional knockdown (KD) of *EWSR1::FLI1* (gray dots) or *EWSR1::ERG* (black dots) for 96 h measured by Affymetrix microarrays and qRT-PCR, respectively.  $n = 3$  biologically independent experiments. **g)** Relative *cIAP1* expression as measured by qRT-PCR of TC-71 and SK-N-MC cells containing a DOX-inducible re-expression construct for *cIAP1*.  $n \geq 8$  biologically independent experiments. Two-sided Mann-Whitney test. **h)** Size-proportional Venn diagrams of genes concordantly regulated 96 h after KD of *EWSR1::FLI1* or upregulation of *cIAP1* in TC-71 and SK-N-MC EwS cells. Minimum  $\log_2$  fold-change  $\pm 0.5$ . Fisher's exact test. **i)** Weighted Gene Correlation Network Analysis (WGCNA) depicting functional gene enrichment of down- or up-regulated genes in *cIAP1* re-expressing EwS cells. Networks depict signatures presenting  $P < 0.05$ , NES  $> 1.25$ . NES, normalized enrichment score. Arrows depict direction of gene regulation. **j)** WGCNA of protein-sets obtained by Pearson correlation analysis of proteins whose expression correlate with *cIAP1* protein expression in four EwS cell lines present in the proteomic dataset from the Cancer Cell Line Encyclopedia (CCLE). Networks depict signatures presenting  $P < 0.05$ , NES  $> 2$ . **k)** Viable cell count of TC-71 and SK-N-MC cells containing a DOX-inducible re-expression construct for *cIAP1* 72 h after treatment with or without DOX. Data are mean and SEM,  $n = 6$  biologically independent experiments. Two-sided Mann-Whitney test. **l)** Relative colony formation as measured in clonogenic index of TC-71 and SK-N-MC cells containing a DOX-inducible re-expression construct for *cIAP1*. Cells were grown either with or without DOX.  $n \geq 6$  biologically independent experiments. Two-sided Mann-Whitney test. Data are mean and SEM. **m)** Relative percentage of area covered by colonies grown in soft-agar of TC-71 and SK-N-MC cells containing a DOX-inducible re-expression construct for *cIAP1*. Cells were grown either with or without DOX.  $n = 4$  biologically independent experiments. Two-sided Mann-Whitney test. **n)** Growth of EwS subcutaneous xenografts of TC-71 and SK-N-MC cells containing a DOX-inducible re-expression construct for *cIAP1* (arrow indicates start of DOX-treatment). Data are represented as means ( $n \geq 5$  animals/group). Two-sided Mann-Whitney test. **o)** *Ex vivo* analysis of tumor weight (left) and representative H&E images of tumors from animals treated without or with DOX (right), scale bar = 5 mm. **p)** *Ex vivo* analysis of mitotic index of xenografted TC-71 and SK-N-MC cell lines. Data are mean,  $n \geq 5$  animals/group. **q)** *Ex vivo* analysis of Ki-67 positivity of xenografted TC-71 and SK-N-MC cell lines. Horizontal bars represent means and whiskers SEM,  $n \geq 5$  animals/group.  $P$ -values were determined via  $\chi^2$  test testing all positives (high and moderate immunoreactivity) versus negatives. Histological images depict representative Ki-67 micrographs. Scale bar = 50  $\mu$ m. **r)** *Ex vivo* analysis of necrotic area of xenografted TC-71 and SK-N-MC cell lines upon *cIAP1* re-expression. Two-sided Mann-Whitney test. **s)** Graph depicts mean number of apoptotic cells per high power field (HPF) of  $n \geq 5$  tumors per group analyzed. (For interpretation of the references to color in this figure legend, the reader is referred to the Web version of this article.)

## 2.2. RNA extraction, reverse transcription, and quantitative Real-Time Polymerase Chain Reaction (qRT-PCR)

Total RNA was isolated using the NucleoSpin RNA kit (Macherey-Nagel, Germany). 1  $\mu$ g of total RNA was reverse-transcribed using High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems, USA). qRT-PCR reactions were performed using SYBR green Mastermix (Applied Biosystems) mixed with diluted cDNA (1:10) and 0.5  $\mu$ M forward and reverse primer (total reaction volume 15  $\mu$ l) on a BioRad CFX Connect instrument and analyzed using BioRad CFX Manager 3.1 software. Gene expression values were calculated using the  $2^{-\Delta\Delta Ct}$  method [14] relative to the housekeeping gene *RPLP0* as internal control. The thermal conditions for qRT-PCR were as follows: heat activation at 95  $^{\circ}$ C for 2 min, DNA denaturation at 95  $^{\circ}$ C for 10 s, and annealing and elongation at 60  $^{\circ}$ C for 20 s (50 cycles), final denaturation at 95  $^{\circ}$ C for 30 s. Oligonucleotides were purchased from MWG Eurofins Genomics (Germany) and are listed below:

*RPLP0* forward: 5'-GAAACTCTGCATTCTCGCTTC-3'  
*RPLP0* reverse: 5'-GGTGAATCCGTCTCCACAG-3'  
*cIAP1* forward: 5'-TGCAACTTCAGATACCACTGG-3'  
*cIAP1* reverse: 5'-CACGAGTCTCTATTAAGCCC-3'  
*EWSR1::FLI1* forward: 5'-GCTCAAGCTCCAAGTCAATATAGC-3'  
*EWSR1::FLI1* reverse: 5'-GAGGCCAGAATTCATGTTATTGC-3'  
*cIAP1* overexpression experiments.

To re-express *cIAP1* at physiological levels, we assessed the baseline expression levels of *cIAP1* in 18 EwS cell lines for which whole-transcriptome data from human Affymetrix Clariom D arrays was available within a published Ewing Sarcoma Cell Line Atlas (ESCLA; triplicates per group per cell line [2]). As suitable models, we chose SK-N-MC and TC-71 cells as they exhibited the lowest baseline *cIAP1* expression among these cell lines and proceeded with cloning as described in Ref. [15]. Briefly, *cIAP1* cDNA was PCR-amplified using a SK-N-MC/TR/shEF1 sample treated with DOX as a template, and using AgeI- and NotI-restriction site containing primers (forward:

5'-ATTAACGGTCCACCATGCACAAAAGTGCCTC-3'; reverse: 5'-TAAT GCGGCCGCTTAAGAGAGAAATGTACGAAC-3'), before cloning it into the multiple cloning site of a modified pTP vector [16]. *cIAP1* non-functional mutants were cloned from the same cDNA using touchdown-PCR. A RING-domain truncated mutant was generated by using a different reverse primer (5'-TAATGCGGCCGCTT AAGAGAGAAATGTACGAACAGTACCCTTGATTATACCAGTTCGTTCTT-CTTGCAAC-3') and a final Tm of 55  $^{\circ}$ C. The generated inserts were double restriction-digested with AgeI and NotI (NEB) and ligated into the pTP backbone [16] using T4 ligase (NEB). Positive clones were identified by colony PCR and cultured in 100 mL of LB Broth containing 100  $\mu$ g/mL ampicillin. Plasmids were extracted and purified using a Midi-Prep Kit (Macherey-Nagel). The correct insertion of full-length *cIAP1* cDNA, or RING-domain deficient mutant was verified by Sanger sequencing (sequencing primers: forward 5'-ACGTATGTCGAGG-TAGGCGT-3'; reverse 5'-TTCGTCTGACGTGGCAGC-3'). Lentiviral particles were generated in HEK293T cells and used for transduction of SK-N-MC and TC-71 EwS cells using polybrene (8  $\mu$ g/mL). Transduced cells were selected with 0.5  $\mu$ g/mL puromycin. Re-expression of *cIAP1* in SK-N-MC and TC-71 cells was achieved by addition of DOX (1  $\mu$ g/mL) to the culture medium. Cells were single-cell cloned and specific clones were selected and tested for re-expression of *cIAP1*. Only the clones exhibiting re-expression levels comparable to the expression FCs after *EWSR1::FLI1* silencing (see above) were selected for functional assays. Cells transfected with the empty vector were used as additional controls as described previously [13].

## 2.3. Transcriptome analyses

To assess the potential effect of *cIAP1* on gene expression in EwS cells, microarray analysis was performed. To this end,  $1.2 \times 10^4$  cells per well were seeded in 6-well plates and treated with 1  $\mu$ g/ $\mu$ l DOX for 72 h (DOX-refreshment after 48 h). Thereafter, total RNA was extracted with the ReliaPrep miRNA Cell and Tissue Miniprep System (Promega) and

RNA quality was assessed with a Bioanalyzer. All samples had an RNA integrity number (RIN) > 9 and were hybridized to Human Affymetrix Clariom D microarrays. Gene expression data were quantile normalized with Transcriptome Analysis Console (v4.0; Thermo Fisher Scientific) using the SST-RMA algorithm as previously described [17]. Annotation of the data was performed using the Affymetrix library for Clariom D Array (version 2, *Homo sapiens*) on gene level. DEGs with consistent and significant FCs across cell lines were identified as follows: Normalized gene expression signals were log<sub>2</sub> transformed. To avoid false discovery artifacts due to the detection of only minimally expressed genes, we excluded all genes with a lower expression value than that observed for *ERG* of the respective cell lines (log<sub>2</sub> expression signal of 7.08 for SK-N-MC and 6.57 for TC-71), which is known to be virtually not expressed in EWSR1::FLI1 positive EwS cell lines [18]. The FCs of both *CIAP1* re-expressing EwS cell lines were calculated for each cell line separately. Then the FCs in the *CIAP1* re-expressing samples were normalized to that of the empty control cells. Then both FCs were averaged to obtain the mean FC per gene across cell lines. DEGs were determined as having a log<sub>2</sub> FC > 0.5 or < -0.5, respectively.

#### 2.4. Gene-Set Enrichment Analysis (GSEA)

To identify enriched gene-sets, genes were ranked by their expression FC between the groups DOX (-) and DOX (+). GSEA was performed using the FGSEA R package (v 3.6.3) based on Gene Ontology (GO) biological processes terms from MSigDB (c5.all.v7.0.symbols.gmt) [19]. GO terms were filtered for statistical significance (adjusted *P* < 0.05) and a normalized enrichment score |(NES)| > 2 or |(NES)| > 1.25 (10,000 permutations), depending on the dataset. In order to construct a network, the Weighted Gene Correlation Network Analysis R package (WGCNA R) [20] was used. Briefly, a binary matrix of GO-terms × genes (where 1 indicates the gene is present in the GO term and 0 indicates it is not) was created. Then, the Jaccard's distance for all possible pairs was computed to create a symmetric GO adjacent matrix. Clusters of similar GO terms were identified using dynamicTreeCut algorithm, and the top 20 % highest edges were selected for visualization. The highest scoring node in each cluster was determined as the cluster label (rName). The obtained network and nodes files were fed into Cytoscape (v 3.8.0) for network design and visualization as previously described [21].

#### 2.5. Proliferation assays

For proliferation assays, 5–8 × 10<sup>5</sup> EwS cells per well (depending on the cell line) were seeded in triplicates per group in 6-well plates and treated with 1 µg/mL DOX for 72 h. Thereafter, cells including their supernatant were harvested and counted using standardized hemocytometers (C-Chip, Biochrom) and the Trypan-Blue (Sigma-Aldrich) exclusion method as described in Ref. [22].

#### 2.6. Clonogenic growth assays

For clonogenic growth assays, EwS cells were seeded in triplicates at low density (2 × 10<sup>3</sup> cells) per well in 12-well plates and grown for 9–11 d (depending on the cell line) with/without DOX-treatment (renewal of DOX or vehicle every 48 h). Thereafter, colonies were stained with crystal violet (Sigma-Aldrich) and colony numbers and areas were measured with the ImageJ Plugin *Colony area*. The clonogenicity index was calculated by multiplying the counted colonies with the corresponding colony area.

#### 2.7. Western blot

Cells were seeded in 6-well plates in RPMI +10% FCS then treated with/without 1 µg/mL DOX. DOX was refreshed after 48h. At 96 h post-seeding, cells were collected by trypsination, pelleted, and lysed in RIPA buffer (SERVA 39244.02) with protease (Sigma Aldrich) and

phosphatase (PHOSSTOP, Roche) inhibitors. Protein was quantified by BCA assay. 10 µg of protein was loaded into 4–20% Tris-HCl gels (BioRad) and separated by SDS-PAGE. Proteins were transferred to PVDF membrane (BioRad) at 200 mA for 1.5 h. Membrane was blocked in 5% milk/TBS-T for 1 h RT then incubated with primary antibodies overnight at 4 °C [anti-*CIAP1* Recombinant Rabbit Monoclonal Antibody (2L0W9) (Invitrogen Cat #MA5-35343) - 1:1,000, 5% milk/TBS-T; anti-GAPDH (14C10) Rabbit mAb, Cell Signaling Technology, #2118S- 1:5,000, 5% milk/TBS-T; anti-*ERG* (EPR3864), Rabbit mAb, Abcam, #ab92513 - 1:1,000, 5% milk/TBS-T)]. Membranes were washed with TBS-T then incubated with HRP-conjugated anti-rabbit secondary (*CIAP1*, *ERG* - 1:2,000, 5% milk/TBS-T; *GAPDH* - 1:10,000, 5% milk/TBS-T) for 1 h RT. Membranes were washed then incubated with ECL substrate (WesternBright™ Sirius™ Chemiluminescent HRP Substrate, Advanta) and chemiluminescence detected with Fusion FX EDGE. Densitometry was calculated using FIJI relative to the respective *GAPDH* loading control.

#### 2.8. Sphere formation assays in soft agar

For the analysis of anchorage-independent growth, EwS cells were pre-treated with/without DOX for 48 h before seeding. A base of 2 mL of agar 1:1 with 2 × DMEM medium was poured in wells of 6-well plates and left for 30–60 min to solidify. Then, 5 × 10<sup>3</sup> cells per well were seeded in 500 µl in triplicates per condition (-/+DOX). Cells were kept in culture for 9–11 d and new medium (-/+DOX) was added on top of each well every 48 h. Spheres were stained with 50 µl of a 5 mg/mL MTT solution that was added dropwise to each well and incubated for 1 h. Pictures of the stained spheres were taken, and their area was analyzed with ImageJ.

#### 2.9. In vivo experiments in mice

3 × 10<sup>6</sup> SK-N-MC or TC-71 EwS cells harboring a re-expression construct for *CIAP1* were injected in a 1:1 mix of cells suspended in PBS with Geltrex Basement Membrane Mix (ThermoFisher) in the right flank of 10–12 weeks old NOD/scid/gamma (NSG) mice as described in Ref. [23]. Tumor diameters were measured every second day with a caliper and tumor volume was calculated by formula  $L \times l^2/2$ , where *L* is the length and *l* the width. When the tumors reached an average volume of 80 mm<sup>3</sup>, mice were randomized in two groups of which one was henceforth treated with 2 mg/mL DOX (Beladox, Bela-pharm, Germany) dissolved in drinking water containing 5% sucrose (Sigma-Aldrich) to induce an *in vivo* re-expression (DOX (+)), whereas the other group only received 5% sucrose (control, DOX (-)). Once tumors of control groups nearly reached an average volume of 1,500 mm<sup>3</sup>, all mice of the experiment were sacrificed by cervical dislocation. Other humane endpoints were determined as follows: Ulcerated tumors, loss of 20% body weight, constant curved or crouched body posture, bloody diarrhea or rectal prolapse, abnormal breathing, severe dehydration, visible abdominal distention, obese Body Condition Scores (BCS), apathy, and self-isolation. All tumor-bearing mice were sacrificed by cervical dislocation at the predefined experimental endpoint, when the mice reached a humane endpoint as listed above. After extraction of the tumors, they were weighted, and a small fraction of each tumor was snap frozen in liquid nitrogen to preserve the RNA isolation, while the remaining tumor tissue was fixed in 4% formalin and embedded in paraffin for immunohistology. Animal experiments were approved by the governments of Upper Bavaria and conducted in accordance with ARRIVE guidelines, recommendations of the European Community (86/609/EEC), and United Kingdom Coordinating Committee on Cancer Research (UKCCCR) guidelines for the welfare and use of animals in cancer research.

## 2.10. Survival analysis

Kaplan-Meier survival analyses were performed in 196 EwS patients (all samples derived from primary tumors that had been previously molecularly confirmed and retrospectively collected) that had been profiled at the mRNA level by gene expression microarrays in previous studies [24–27]. Microarray data generated on Affymetrix HG-U133Plus2.0, Affymetrix HuEx-1.0-st or Amersham/GE Healthcare CodeLink microarrays of the EwS tumors (Gene Expression Omnibus (GEO) accession codes: [GSE63157](#) [24], [GSE12102](#) [25], [GSE17618](#) [26], [GSE34620](#) [27] provided with clinical annotations were normalized separately as previously described [6]. Genes represented on all microarray platforms were kept for further analysis. Batch effects were removed using the ComBat algorithm [28]. Data processing was done in R.

## 2.11. Statistical analysis and software

Statistical data analysis was performed using PRISM 9 (GraphPad Software Inc., Ca, USA) on the raw data. If not specified otherwise in the figure legends, comparison of two groups in functional *in vitro* experiments was carried out using a two-sided Mann-Whitney test. If not specified otherwise in the figure legends, data are presented as dot plots with horizontal bars representing means and whiskers representing the standard error of the mean (SEM). Sample size for all *in vitro* experiments were chosen empirically. For *in vivo* experiments, the sample size was predetermined using power calculations with  $\beta = 0.8$  and  $\alpha < 0.05$  based on preliminary data and in compliance with the 3R principles (replacement, reduction, refinement). Statistical differences between the groups were assessed by a Mantel-Haenszel test.

## CRediT authorship contribution statement

**Florencia Cidre-Aranaz:** Writing – review & editing, Writing – original draft, Visualization, Validation, Resources, Methodology, Investigation, Funding acquisition, Formal analysis, Data curation, Conceptualization. **Florian H. Geyer:** Writing – review & editing, Methodology, Investigation. **Tilman L.B. Hölting:** Writing – review & editing, Investigation. **Kimberley M. Hanssen:** Investigation, Methodology, Validation. **Tobias Faehling:** Writing – review & editing, Investigation, Data curation. **Alina Ritter:** Writing – review & editing, Investigation. **Malenka Zimmermann:** Writing – review & editing, Investigation. **Lianghao Mao:** Writing – review & editing, Methodology, Investigation. **Javier Alonso:** Writing – review & editing, Resources. **Ana Sastre:** Resources. **Ashok Kumar Jayavelu:** Writing – review & editing, Resources, Methodology. **Maximilian M.L. Knott:** Writing – review & editing, Resources, Methodology, Investigation. **Julian Musa:** Writing – review & editing, Methodology, Investigation. **Thomas G.P. Grünewald:** Writing – review & editing, Writing – original draft, Visualization, Supervision, Resources, Project administration, Funding acquisition, Conceptualization.

## Funding information

This study was mainly supported by a grant of the Hubertus Trettner Foundation (to F.C.-A.). The laboratory of T.G.P.G. and F.C.-A. is additionally supported by grants from the Matthias-Lackas Foundation, the Dr. Leopold und Carmen Ellinger Foundation, the German Cancer Aid (DKH-70112257, DKH-70114111, DKH-70115315), the Dr. Rolf M. Schwiete foundation (2020-028 and 2022-31), the SMARCB1 association, the German Ministry of Education and Research (BMBF; SMART-CARE and HEROES-AYA), the Barbara and Wilfried Mohr foundation, and the European Research Council (ERC CoG 2023 #101122595). All views and opinions expressed are however those of the authors only and do not necessarily reflect those of the European Union or the European Research Council. Neither the European Union nor the granting

authority can be held responsible for them.

Florian Henning Geyer, Tobias Faehling, Malenka Zimmermann, and Alina Ritter were supported by the German Academic Scholarship Foundation. Julian Musa was supported by the Ministry of Education and Research (BMBF; HEROES-AYA). In addition, Tobias Faehling was supported by the Heinrich F.C. Behr foundation, and Florian Henning Geyer, Tilman Luis Benedikt Hölting, and Alina Ritter were supported by the German Cancer Aid through the 'Mildred-Scheel-Doctoral Program'. Malenka Zimmermann was supported by a doctoral scholarship from the Kind-Philipp-Stiftung.

## Declaration of competing interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

## Acknowledgements

We would like to thank Nadine Gmelin, Stefanie Kutschmann, Felina Zahnow, and Sabrina Knoth for their expert technical assistance, and Claudia Schmidt from the Light Microscopy Facility (German Cancer Research Center (DKFZ), Heidelberg, Germany) for her meticulous work in conducting immunohistochemical stainings.

## Appendix A. Supplementary data

Supplementary data to this article can be found online at <https://doi.org/10.1016/j.canlet.2026.218389>.

## Data availability

Original microarray data that support the findings of this study has been deposited at the National Center for Biotechnology Information (NCBI) GEO and can be found under accession numbers [GSE304158](#) and [GSE165929](#).

## References

- [1] T.G.P. Grünewald, F. Cidre-Aranaz, D. Surdez, E.M. Tomazou, E. de Álava, H. Kovar, et al., Ewing sarcoma, *Nat. Rev. Dis. Primers* 4 (1) (2018 05) 5.
- [2] M.F. Orth, D. Surdez, T. Faehling, A.C. Ehlers, A. Marchetto, S. Grossetête, et al., Systematic multi-omics cell line profiling uncovers principles of Ewing sarcoma fusion oncogene-mediated gene regulation, *Cell Rep.* 41 (10) (2022 Dec 6) 111761.
- [3] D. Warde-Farley, S.L. Donaldson, O. Comes, K. Zuberi, R. Badrawi, P. Chao, et al., The GeneMANIA prediction server: biological network integration for gene prioritization and predicting gene function, *Nucleic Acids Res.* 38 (2010 July) W214–W220. Web Server issue.
- [4] B. Dumétier, A. Zadoroznyj, J. Berthelet, S. Causse, J. Allègre, P. Bourgeois, et al., cIAP1/TRAF2 interplay promotes tumor growth through the activation of STAT3, *Oncogene* 42 (3) (2023 Jan) 198–208.
- [5] M.J.M. Bertrand, S. Milutinovic, K.M. Dickson, W.C. Ho, A. Boudreault, J. Durkin, et al., cIAP1 and cIAP2 facilitate cancer cell survival by functioning as E3 ligases that promote RIP1 ubiquitination, *Mol. Cell* 30 (6) (2008 June 20) 689–700.
- [6] M.C. Baldauf, M.F. Orth, M. Dallmayer, A. Marchetto, J.S. Gerke, R.A. Rubio, et al., Robust diagnosis of Ewing sarcoma by immunohistochemical detection of super-enhancer-driven EWSR1-ETS targets, *Oncotarget* 9 (2) (2018 Jan 5) 1587–1601.
- [7] F.H. Geyer, A. Ritter, S. Kinn-Gurzo, T. Faehling, J. Li, A. Jarosch, et al., Comprehensive DSRCT multi-omics analyses unveil CACNA2D2 as a diagnostic hallmark and super-enhancer-driven EWSR1:WT1 signature gene, *Cancer Commun. Lond Engl.* 45 (6) (2025 June) 702–708.
- [8] M.M. Aynaud, O. Mirabeau, N. Gruel, S. Grossetête, V. Boeva, S. Durand, et al., Transcriptional programs define intratumoral heterogeneity of ewing sarcoma at single-cell resolution, *Cell Rep.* 30 (6) (2020 Feb 11) 1767–1779.e6.
- [9] F. Tirede, K. Laud-Duval, A. Prieur, B. Delorme, P. Charbord, O. Delattre, Mesenchymal stem cell features of Ewing tumors, *Cancer Cell* 11 (5) (2007 May) 421–429.
- [10] M. Kasan, F.H. Geyer, J. Siebenlist, M. Sill, R. Öllinger, T. Faehling, et al., Genomic and phenotypic stability of fusion-driven pediatric sarcoma cell lines, *Nat. Commun.* 16 (1) (2025 Jan 3) 380.
- [11] R. Tsukada, M. Nomura, T. Ueno, H. Okuyama, Inhibition of cIAP1 in the effective suppression of chemotherapy-resistant hepatoblastoma, *Oncol. Rep.* 47 (4) (2022 Apr) 79.

- [12] H.H. Cheung, S. Plenchette, C.J. Kern, D.J. Mahoney, R.G. Korneluk, The RING domain of cIAP1 mediates the degradation of RING-bearing inhibitor of apoptosis proteins by distinct pathways, *Mol. Biol. Cell* 19 (7) (2008 July) 2729–2740.
- [13] F. Cidre-Aranaz, J. Li, T.L.B. Hölting, M.F. Orth, R. Imle, S. Kutschmann, et al., Integrative gene network and functional analyses identify a prognostically relevant key regulator of metastasis in Ewing sarcoma, *Mol. Cancer* 21 (1) (2022 Jan 3) 1.
- [14] K.J. Livak, T.D. Schmittgen, Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method, *Methods San Diego Calif* 25 (4) (2001 Dec) 402–408.
- [15] M.M.L. Knott, F. Cidre-Aranaz, Ewing sarcoma-specific (Re)expression models, *Methods Mol. Biol. Clifton NJ* 2226 (2021) 119–138.
- [16] F. Bauernfeind, A. Rieger, F.A. Schildberg, P.A. Knolle, J.L. Schmid-Burgk, V. Hornung, NLRP3 inflammasome activity is negatively controlled by miR-223, *J. Immunol. Baltim Md* 189 (8) (1950. 2012 Oct 15) 4175–4181.
- [17] A. Marchetto, S. Ohmura, M.F. Orth, M.M.L. Knott, M.V. Colombo, C. Arrigoni, et al., Oncogenic hijacking of a developmental transcription factor evokes vulnerability toward oxidative stress in Ewing sarcoma, *Nat. Commun.* 11 (1) (2020 15) 2423.
- [18] B.D. Crompton, C. Stewart, A. Taylor-Weiner, G. Alexe, K.C. Kurek, M.L. Calicchio, et al., The genomic landscape of pediatric Ewing sarcoma, *Cancer Discov.* 4 (11) (2014 Nov) 1326–1341.
- [19] A. Subramanian, P. Tamayo, V.K. Mootha, S. Mukherjee, B.L. Ebert, M.A. Gillette, et al., Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles, *Proc. Natl. Acad. Sci. U. S. A.* 102 (43) (2005 Oct 25) 15545–15550.
- [20] P. Langfelder, S. Horvath, WGCNA: an R package for weighted correlation network analysis, *BMC Bioinf.* 9 (2008 Dec 29) 559.
- [21] S.M. Waszak, G.W. Robinson, B.L. Gudenas, K.S. Smith, A. Forget, M. Kojic, et al., Germline elongator mutations in Sonic Hedgehog medulloblastoma, *Nature* 580 (7803) (2020 Apr) 396–401.
- [22] C.M. Funk, J. Musa, Proliferation assessment by trypan blue exclusion in ewing sarcoma, *Methods Mol. Biol. Clifton NJ* 2226 (2021) 151–158.
- [23] F. Cidre-Aranaz, S. Ohmura, Tumor growth analysis of ewing sarcoma cell lines using subcutaneous xenografts in mice, *Methods Mol. Biol. Clifton NJ* 2226 (2021) 191–199.
- [24] S.L. Volchenboun, J. Andrade, L. Huang, D.A. Barkauskas, M. Krailo, R.B. Womer, et al., Gene expression profiling of ewing sarcoma tumors reveals the prognostic importance of tumor-stromal interactions: a report from the children's oncology group, *J. Pathol. Clin. Res.* 1 (2) (2015 Apr) 83–94.
- [25] K. Scotlandi, D. Remondini, G. Castellani, M.C. Manara, F. Nardi, L. Cantiani, et al., Overcoming resistance to conventional drugs in Ewing sarcoma and identification of molecular predictors of outcome, *J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol.* 27 (13) (2009 May 1) 2209–2216.
- [26] S. Savola, A. Klami, S. Myllykangas, C. Manara, K. Scotlandi, P. Picci, et al., High expression of complement component 5 (C5) at tumor site associates with superior survival in Ewing's sarcoma family of tumour patients, *ISRN Oncol.* 2011 (2011) 168712.
- [27] S. Postel-Vinay, A.S. Véron, F. Tirode, G. Pierron, S. Reynaud, H. Kovar, et al., Common variants near TARDBP and EGR2 are associated with susceptibility to Ewing sarcoma, *Nat. Genet.* 44 (3) (2012 Feb 12) 323–327.
- [28] C.K. Stein, P. Qu, J. Epstein, A. Buros, A. Rosenthal, J. Crowley, et al., Removing batch effects from purified plasma cell gene expression microarrays with modified ComBat, *BMC Bioinf.* 16 (2015 Feb 25) 63.